Early sepsis recognition: how difficult can this be?
- PMID: 38840224
- PMCID: PMC11155093
- DOI: 10.1186/s13054-024-04975-3
Early sepsis recognition: how difficult can this be?
Conflict of interest statement
EJGΒ has received honoraria from Abbott Products Operations, bioMérieux, Brahms GmbH, GSK, InflaRx GmbH and Sobi; independent educational grants from Abbott Products Operations, AbbVie, bioMérieux Inc, InCyte, Johnson & Johnson, MSD, UCD and Sobi; and funding from the Horizon 2020 Marie Skłodowska-Curie International Training Network “the European Sepsis Academy” (granted to the National and Kapodistrian University of Athens), the Horizon 2020 European Grants ImmunoSep and RISC in COVID and the Horizon Health grant EPIC-CROWN-2 and POINT (granted to the Hellenic Institute for the Study of Sepsis). JE-O is a co-founder, shareholder, and CSO of ViroGates, Denmark, and named inventor on patents on suPAR owned by Copenhagen University Hospital Hvidovre, Denmark. The other authors do not disclose any conflict of interest.
Comment on
-
qSOFA combined with suPAR for early risk detection and guidance of antibiotic treatment in the emergency department: a randomized controlled trial.Crit Care. 2024 Feb 6;28(1):42. doi: 10.1186/s13054-024-04825-2. Crit Care. 2024. PMID: 38321472 Free PMC article. Clinical Trial.
References
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical